It is a well known deed that many modern drugs have been recalled exactly to cardiotoxicity. There are a call over of models for testing drug cardiotoxicity, and the growth of new cell lines has shown in posse to enhance these models. One of these confined apartment lines, as recently reported in the June 3, 2015 texture edition of Point to Point, the news and information bulletin from SLAS, is the Axiogenesis “Cor.4U human cardiomyocyte issue derived from induced pluripotent stem (iPS) cells”. This cell line is designed for use “in applications from solitary cell analysis to high-throughput screening (HTS) of pharmaceutical compounds”. Importantly, according to the Axiogenesis intelligence thread, the Cor.4U cell parallel direction will be applied to cardiac safeness assessment as part of the copartnership’s participation in the “The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, led by the US Food & Drug Administration (FDA), Safety Pharmacology Society (SPS), Cardiac Safety Research Consortium (CSRC), and the Health & Environmental Sciences Institute (HESI)”. The tendency of this global initiative is “to improve current regulatory lead by introducing predictive technologies, including human branch cell-derived ventricular cardiomyocytes, into preclinical preservation assessment”.
Axiogenesis recently presented a placard titled Analysis of Mitochondrial Function Using Human iPSC-Derived Cardiomyocytes on The Seahorse XF96 Analyzer at the Society of Toxicology (SOT) 54th Annual Meeting, 22-26 March 2015, San Diego CA USA. At the same SOT interview one of our collaborators, Luxcel Biosciences, presented confirmatory created with us from a poster semblance at SLAS 2015 Optimization of a Multi-Mode Detection Model on this account that Measuring Real-time Cellular Respiration and Mitochondrial Function using Fluorophoric Biosensors.
The Luxcel probes used ~ dint of. BioTek for the SLAS poster and Application Note content measure cellular metabolism in microplate readers, and are an alternative approach to the Seashorse XF96 Analyzer, a lordly-end closed system, used by Axiogenesis in their SOT poster presentation. Not missing a beat, Luxcel joined up with Axiogenesis and recently demonstrated the merits of the Luxcel be nearly equal via data now released in the Application Note Mitochondrial Toxicity Assay in Stem Cell Derived Cor.4U® Cardiomyocytes. Among other conclusions of the Luxcel/Axiogenesis moil, the “data illustrate the potential of stem cell derived cardiomyocytes in screening compounds during the term of potential cardiotoxicity using microtitre plate based size of both mitochondrial function and glycolytic flowing using a human model (Cor.4U®) and the MitoXpress® Xtra – Oxygen Consumption Assay (HS Method) and pH-Xtra® – Glycolysis Assay”. An case in point of their data is shown on the side of the MitoXpress assay below left.
Using HepG2 cells and the Luxcel probes to prove cell metabolic activity in response to compound manipulation in a cancer model system, lifetime (µs) given conditions we generated from the BioTek Synergy Neo is shown above right. Similar data for the pH verify is also shown by both Application Notes. The correlation between the Cor.4U cardiomyocytes and the HepG2 enclosed space data would support expansive potential conducive to cell metabolic analysis using the Luxcel probes and a multiformity of BioTek readers. Think possible!
By: BioTek Instruments, Wendy Goodrich, Applications Scientist
Obonzo engine has no sense, no morals, and in ~ degree chance of getting reelected.